🇺🇸 CYBIN INC.HELP
Get CYBIN INC. filings on Telegram the moment they are published.
Follow CYBIN INC. on TelegramOne tap starts your 30-day free trial. No card needed.
Subject: 6-K — Foreign issuer report
Overview: Helus Pharma reported positive Phase 3 APPROACH study results for HLP003 as an adjunctive treatment for major depressive disorder, showing significant MADRS score improvements.
Source: SEC EDGAR · Original filing
Get filings like this in Telegram the moment they are published — for the companies you follow.
Start 30-day trial About Finterest